SETH LERNER to Carcinoma in Situ
This is a "connection" page, showing publications SETH LERNER has written about Carcinoma in Situ.
Connection Strength
3.064
-
Phase 2 Trial of Atezolizumab in Bacillus Calmette-Gu?rin-unresponsive High-risk Non-muscle-invasive Bladder Cancer: SWOG S1605. Eur Urol. 2023 12; 84(6):536-544.
Score: 0.709
-
Fluorescence and white light cystoscopy for detection of carcinoma in situ of the urinary bladder. Urol Oncol. 2012 May-Jun; 30(3):285-9.
Score: 0.299
-
Editorial comment. J Urol. 2010 Jul; 184(1):79-80.
Score: 0.285
-
Association of p53 and p21 expression with clinical outcome in patients with carcinoma in situ of the urinary bladder. Urology. 2003 Jun; 61(6):1140-5.
Score: 0.175
-
Cyclooxygenase-2 is highly expressed in carcinoma in situ and T1 transitional cell carcinoma of the bladder. J Urol. 2003 Mar; 169(3):938-42.
Score: 0.172
-
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Gu?rin-exposed High-risk Non-muscle-invasive Bladder Cancer. Eur Urol. 2022 07; 82(1):34-46.
Score: 0.158
-
E-cadherin immunostaining of bladder transitional cell carcinoma, carcinoma in situ and lymph node metastases with long-term followup. J Urol. 2001 May; 165(5):1473-9.
Score: 0.151
-
E-cadherin expression predicts clinical outcome in carcinoma in situ of the urinary bladder. Urology. 2001 Jan; 57(1):60-5.
Score: 0.148
-
Intravesical nadofaragene firadenovec gene therapy for BCG-unresponsive non-muscle-invasive bladder cancer: a single-arm, open-label, repeat-dose clinical trial. Lancet Oncol. 2021 01; 22(1):107-117.
Score: 0.147
-
Prognostic value of P53 nuclear accumulation and histopathologic features in T1 transitional cell carcinoma of the urinary bladder. Urology. 2000 Nov 01; 56(5):735-40.
Score: 0.146
-
Endocavitary treatment for upper tract urothelial carcinoma: A meta-analysis of the current literature. Urol Oncol. 2019 07; 37(7):430-436.
Score: 0.130
-
Critical analysis and validation of lymph node density as prognostic variable in urothelial carcinoma of bladder. Urol Oncol. 2013 May; 31(4):480-6.
Score: 0.075
-
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patients. J Urol. 2010 May; 183(5):1757-63.
Score: 0.070
-
p53 expression in patients with advanced urothelial cancer of the urinary bladder. BJU Int. 2010 Feb; 105(4):489-95.
Score: 0.067
-
Prostatic transitional cell carcinoma: pathologic features and clinical management. Expert Rev Anticancer Ther. 2007 Aug; 7(8):1155-62.
Score: 0.058
-
A comparison of hexaminolevulinate fluorescence cystoscopy and white light cystoscopy for the detection of carcinoma in situ in patients with bladder cancer: a phase III, multicenter study. J Urol. 2007 Jul; 178(1):68-73; discussion 73.
Score: 0.057
-
Characteristics and outcomes of patients with carcinoma in situ only at radical cystectomy. Urology. 2006 Sep; 68(3):538-42.
Score: 0.055
-
Concomitant carcinoma in situ is a feature of aggressive disease in patients with organ-confined TCC at radical cystectomy. Eur Urol. 2007 Jan; 51(1):152-60.
Score: 0.055
-
Prostatic involvement by transitional cell carcinoma in patients with bladder cancer and its prognostic significance. Hum Pathol. 2006 Jun; 37(6):726-34.
Score: 0.054
-
Bropirimine immunotherapy of upper urinary tract carcinoma in situ. Urology. 1996 Jul; 48(1):28-32.
Score: 0.027
-
Phase III study of molecularly targeted adjuvant therapy in locally advanced urothelial cancer of the bladder based on p53 status. J Clin Oncol. 2011 Sep 01; 29(25):3443-9.
Score: 0.019
-
Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994 Feb 01; 54(3):784-8.
Score: 0.006